A carregar...

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

Epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) is currently the standard therapy for EGFR-mutated non–small cell lung cancer (NSCLC). Gefitinib is the first EGFR-TKI marketed in Indonesia and has been used since 2012 in Dr. Soetomo General Hospital, a tertiary hospital in Sura...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Laksmi Wulandari, Anna Febriani, Farah Fatmawati, Gatot Soegiarto
Formato: Artigo
Idioma:Inglês
Publicado em: Thieme Medical Publishers, Inc. 2018-07-01
Colecção:Asian Journal of Oncology
Assuntos:
Acesso em linha:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1676872
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!